|
| related topics |
| {product, candidate, development} |
| {regulation, change, law} |
| {personnel, key, retain} |
| {product, liability, claim} |
| {property, intellectual, protect} |
| {control, financial, internal} |
| {competitive, industry, competition} |
|
|
Our clinical trials may fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.
We have a history of losses and expect to incur losses and negative operating cash flows for the near future, and we may never achieve sustained profitability
We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, we could lose our rights to those technologies and drug candidates.
We have limited marketing experience, sales force or distribution capabilities, and if our products are approved, we may not be able to commercialize them successfully.
If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts.
If physicians and patients do not accept our products, we may not recover our investment.
Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.
Risks Related to Our Industry
The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third parties.
Full 10-K form ▸
|
|
| related documents |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 1000694--3/6/2006--NOVAVAX_INC |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 1123361--3/6/2007--VIASYS_HEALTHCARE_INC |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 949858--3/16/2006--SONUS_PHARMACEUTICALS_INC |
| 927761--4/9/2008--MYMETICS_CORP |
| 899866--2/23/2009--ALEXION_PHARMACEUTICALS_INC |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 858803--12/21/2007--AVANIR_PHARMACEUTICALS |
| 874015--3/16/2007--ISIS_PHARMACEUTICALS_INC |
| 1020214--2/26/2007--CERUS_CORP |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 1436083--7/20/2009--New_Millennium_Products |
| 78003--2/29/2008--PFIZER_INC |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 23259--3/31/2006--CT_COMMUNICATIONS_INC_/NC |
| 1114200--2/28/2007--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 834365--3/31/2009--BIOLIFE_SOLUTIONS_INC |
| 28626--9/13/2006--LIFECORE_BIOMEDICAL_INC |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 876343--4/17/2006--BIOTIME_INC |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
|